Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22363287 | 0.97 | KDM4E (0.49) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL25573950 | 0.97 | KDM4E (0.46) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL19464638 | 0.95 | KDM4E (0.46) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL19987500 | 0.89 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL19853004 | 0.85 | KDM4E (0.49) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL19003579 | 0.83 | KDM4E (0.40) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL26061393 | 0.81 | KDM4E (0.45) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL21024658 | 0.78 | KDM4E (0.40) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL22379193 | 0.76 | TSHR (0.38) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL18948444 | 0.76 | KDM4E (0.39) | KDM4EALDH1A1HPGDL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | AR, SHBG, BRCA1 | KDM4E 1638/4885ALDH1A1 1480/4885HPGD 620/4885 |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | AR, FSHR, ESRRB | KDM4E 1961/4885ALDH1A1 2525/4885HPGD 1037/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | KDM4E 958/4885ALDH1A1 1171/4885HPGD 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.